ENTITY
Yichang HEC Changjiang Pharma

Yichang HEC Changjiang Pharma (1558 HK)

45
Analysis
Health CareHong Kong
YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs. The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.
more
Refresh
04 Jan 2024 09:30

HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China

HEC Pharma should benefit from the upsurge in respiratory illness in China. With a forward P/E of 4.8x and 14% YoY EPS growth expectation for 2024,...

Logo
606 Views
Share
02 Oct 2023 21:57

HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China

HEC Pharma reports impressive revenue growth of 148% YoY in 1H23, driven by strong sales of Kewei for influenza treatment. The company obtained...

Logo
423 Views
Share
bullishShriram Finance
07 Jan 2024 05:10

Index Rebalance & ETF Flow Recap: HSCEI, HSCI, KRX New Deal, NIFTY50, NEXT50, CNXBANK

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Logo
749 Views
Share
bullishWuXi XDC Cayman
03 Jan 2024 05:00

HSCI Index Rebalance Preview and Stock Connect: Potential Changes in March

There could be nearly 58 adds/deletes for the HSCI in September. That will trigger changes to the Southbound Stock Connect list and increase flows...

Logo
917 Views
Share
bearishOvctek China
28 May 2023 09:22

China Healthcare Weekly (May.26)- 9th National VBP, China's Strength in ADC Field, Ovctek, Eyebright

The 9th national VBP is coming, but policy could change from 2026.We see positive factors in the performance of Chinese company in ADC field, who...

Logo
357 Views
Share
x